NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies

NCT05023486 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

121

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced or Metastatic Solid Tumor Malignancies

Interventions

DRUG: NP-G2-044 Monotherapy
DRUG: Anti-PD-1 Therapy
DRUG: NP-G2-044 Combination therapy

Sponsor

Novita Pharmaceuticals, Inc.